Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TTBK1 | Q5TCY1 | 4/20 | 0.48 |
| ▸ | TTBK2 | Q6IQ55 | 4/20 | 0.48 |
| ▸ | JAK2 | O60674 | 1/20 | 0.47 |
| ▸ | AKT2 | P31751 | 1/20 | 0.45 |
| ▸ | GSK3B | P49841 | 1/20 | 0.45 |
| ▸ | CSF1R | P07333 | 1/20 | 0.45 |
| ▸ | JAK3 | P52333 | 5/20 | 0.45 |
| ▸ | CDC7 | O00311 | 1/20 | 0.44 |
| ▸ | DBF4 | Q9UBU7 | 1/20 | 0.44 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.44 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.44 |
| ▸ | LCK | P06239 | 1/20 | 0.43 |
| ▸ | JAK1 | P23458 | 1/20 | 0.43 |
| ▸ | HPGDS | O60760 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20220690 | 0.85 | TTBK1 (0.49) | TTBK1TTBK2JAK2AKT2GSK3B | |
| SCHEMBL24345975 | 0.82 | AKT2 (0.50) | TTBK1TTBK2JAK2AKT2GSK3B | |
| SCHEMBL14355258 | 0.81 | JAK2 (0.47) | TTBK1TTBK2JAK2AKT2GSK3B | |
| Hydrochloric Acid SCHEMBL4974811 | 0.81 | AKT2 (0.49) | TTBK1TTBK2JAK2AKT2GSK3B | |
| SCHEMBL12561826 | 0.80 | JAK3 (0.44) | TTBK1TTBK2JAK2AKT2GSK3B | |
| SCHEMBL21715896 | 0.80 | TTBK1 (0.45) | TTBK1TTBK2JAK2AKT2GSK3B | |
| SCHEMBL27020416 | 0.80 | TTBK1 (0.45) | TTBK1TTBK2JAK2AKT2GSK3B | |
| SCHEMBL13961511 | 0.78 | JAK3 (0.45) | TTBK1TTBK2JAK2AKT2GSK3B | |
| SCHEMBL14907686 | 0.77 | JAK2 (0.44) | TTBK1TTBK2JAK2AKT2GSK3B | |
| SCHEMBL18238494 | 0.75 | ADORA2A (0.40) | TTBK1TTBK2JAK2AKT2GSK3B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024042448-A1 | AN IMPROVED PROCESS FOR THE PREPARATION OF RUXOLITINIB | GRANULES INDIA LIMITED (IN) | 2024-02-29 | — | — | WO | disclosed |
| WO-2023223253-A1 | PROCESS FOR PREPARATION OF RUXOLITINIB | GLENMARK LIFE SCIENCES LIMITED (IN) | 2023-11-23 | — | — | WO | disclosed |
| CN-111712498-B | Substituted bicyclic heterocyclic compounds as PRMT5 inhibitors | 鲁平有限公司 | 2023-09-29 | — | — | CN | disclosed |
| US-20230055961-A1 | PENTAFLUOROBENZENESULFONAMIDE DERIVATIVES AND USES THEREOF | DUNAD THERAPEUTICS LTD. (GB) | 2023-02-23 | — | — | US | disclosed |
| US-20210139484-A1 | DIHYDROISOQUINOLINE-2(1H)-CARBOXAMIDE AND RELATED COMPOUNDS AND THEIR USE IN TREATING MEDICAL CONDITIONS | GOSSAMER BIO SERVICES INC (US) | 2021-05-13 | — | — | US | disclosed |
| EP-3154962-B1 | PHOSPHATIDYLINOSITOL 3-KINASE INHIBITORS | GILEAD SCIENCES INC (US) | 2019-08-07 | — | — | EP | disclosed |
| US-20190040080-A1 | BIARYL KINASE INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2019-02-07 | — | — | US | disclosed |
| US-9938276-B2 | 6,5-bicyclic octahydropyrrolopyridine orexin receptor antagonists | MERCK SHARP & DOHME CORP. (US) | 2018-04-10 | — | — | US | disclosed |
| WO-2017215627-A1 | PREPARATION METHOD FOR CHIRAL PYRROLOPYRIMIDINE COMPOUND | 正大天晴药业集团股份有限公司 | 2017-12-21 | — | — | WO | disclosed |
| US-20170320874-A1 | 6,5-BICYCLIC OCTAHYDROPYRROLOPYRIDINE OREXIN RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME CORP. (US) | 2017-11-09 | — | — | US | disclosed |
| US-20110015212-A1 | PYRIMIDINONES AS PI3K INHIBITORS | INCYTE CORPORATION | 2011-01-20 | — | — | US | disclosed |
| US-20100311766-A1 | ANTIBACTERIAL COMPOSITIONS | BIOTA EUROPE LTD (GB) | 2010-12-09 | — | — | US | disclosed |
| US-20090318436-A1 | Fused heterocyclic derivatives and methods of use | AMGEN INC. (US) | 2009-12-24 | — | — | US | disclosed |
| US-20090197877-A1 | Antibacterial Compositions | PROLYSIS LTD. (GB) | 2009-08-06 | — | — | US | disclosed |
| WO-2009080682-A1 | PYRROLO[2,3-D]PYRIMIDINE DERIVATIVES AS CGRP RECEPTOR ANTAGONISTS | GLAXO GROUP LIMITED (GB) | 2009-07-02 | — | — | WO | disclosed |
| WO-2009080682-A1 | PYRROLO[2,3-D]PYRIMIDINE DERIVATIVES AS CGRP RECEPTOR ANTAGONISTS | GLAXO GROUP LIMITED (GB) | 2009-07-02 | — | — | WO | disclosed |
| US-20090124612-A1 | Fused heterocyclic derivatives and methods of use | AMGEN INC. (US) | 2009-05-14 | — | — | US | disclosed |
| US-7435823-B2 | Compounds and methods of use | AMGEN INC. (US) | 2008-10-14 | — | — | US | disclosed |
| WO-2008075172-A2 | NICOTINAMIDE DERIVATIVES AS INHIBITORS OF H-PGDS AND THEIR USE FOR TREATING PROSTAGLANDIN D2 MEDIATED DISEASES | PFIZER PRODUCTS INC. (US) | 2008-06-26 | — | — | WO | disclosed |
| US-20080146569-A1 | Nicotinamide Derivatives | PFIZER INC. | 2008-06-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090318436-A1 | Fused heterocyclic derivatives and methods of use | HGF, HGFAC, MET | TTBK1 2311/4885TTBK2 2390/4885JAK2 320/4885 |
| US-20190040080-A1 | BIARYL KINASE INHIBITORS | AAK1, CAMKK1, CAMKK2 | TTBK1 27/4885TTBK2 49/4885JAK2 1385/4885 |
| US-20090124612-A1 | Fused heterocyclic derivatives and methods of use | HGF, HGFAC, MET | TTBK1 2311/4885TTBK2 2390/4885JAK2 320/4885 |
| US-20090197877-A1 | Antibacterial Compositions | CYCS, COX6C, INTS6 | TTBK1 2335/4885TTBK2 2710/4885JAK2 3463/4885 |
| US-20100311766-A1 | ANTIBACTERIAL COMPOSITIONS | C5, AGK, CYCS | TTBK1 1463/4885TTBK2 2480/4885JAK2 2733/4885 |
| US-20210139484-A1 | DIHYDROISOQUINOLINE-2(1H)-CARBOXAMIDE AND RELATED COMPOUNDS AND THEIR USE IN TREATING MEDICAL CONDITIONS | ULK1, PHKG2, PHKG1 | TTBK1 225/4885TTBK2 411/4885JAK2 718/4885 |
| US-20080146569-A1 | Nicotinamide Derivatives | NNT, NAMPT, NADK | TTBK1 3469/4885TTBK2 3682/4885JAK2 2663/4885 |
| US-20230055961-A1 | PENTAFLUOROBENZENESULFONAMIDE DERIVATIVES AND USES THEREOF | FURIN, PFAS, CFTR | TTBK1 3603/4885TTBK2 2919/4885JAK2 389/4885 |
| US-20110015212-A1 | PYRIMIDINONES AS PI3K INHIBITORS | PIK3CA, PIK3CD, PIK3CB | TTBK1 1356/4885TTBK2 1560/4885JAK2 37/4885 |
| US-20170320874-A1 | 6,5-BICYCLIC OCTAHYDROPYRROLOPYRIDINE OREXIN RECEPTOR ANTAGONISTS | HCRTR2, HCRTR1, NPY5R | TTBK1 4228/4885TTBK2 4068/4885JAK2 3105/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.